Recent blog posts
Behcet oral ulcers Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Behcet oral ulcers Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Behcet oral ulcers indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Recurrent aphthous stomatitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Recurrent aphthous stomatitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Recurrent aphthous stomatitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Geographic tongue Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Geographic tongue Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Geographic tongue indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Burning mouth syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Burning mouth syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Burning mouth syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Melinta Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Melinta Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Melinta Therapeutics BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
MGI Pharma, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
MGI Pharma, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
MGI Pharma, Inc BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Microbion Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Microbion Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Microbion Corporation BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Micromet, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Micromet, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Micromet, Inc BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Oral leukoplakia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Oral leukoplakia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Oral leukoplakia indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Oral submucous fibrosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Oral submucous fibrosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Oral submucous fibrosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Oral erythroplakia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Oral erythroplakia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Oral erythroplakia indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Oral lichen planus Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Oral lichen planus Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Oral lichen planus indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →